Key Developments: Compugen Ltd (CGEN.PH)

CGEN.PH on Philadelphia Stock Exchange

5.70USD
14 May 2013
Price Change (% chg)

$-0.10 (-1.72%)
Prev Close
$5.80
Open
$5.70
Day's High
$5.70
Day's Low
$5.70
Volume
100
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Latest Key Developments (Source: Significant Developments)

Compugen Ltd Announces Validation Results For A Second Potential Immune Checkpoint Target For Cancer Immunotherapy
Wednesday, 27 Jun 2012 07:00am EDT 

Compugen Ltd announced results demonstrating the therapeutic potential of CGEN-15022, a Compugen-discovered B7/CD28-like membrane protein, as an immune checkpoint target for treatment of multiple cancers. The results indicate that CGEN-15022 is expressed in numerous types of epithelial cancers with significant unmet clinical needs, such as liver, colorectal, lung and ovarian cancers. These findings, together with previously disclosed results pointing to its negative costimulatory activity, strongly support CGEN-15022’s potential as a compelling drug target for treatment of these cancers through monoclonal antibody (mAb) therapy, an area of great interest to the pharmaceutical industry. The Company previously announced that CGEN-15001T, the first protein to undergo validation, of nine novel molecules predicted in silico by Compugen to be B7/CD28-like proteins, demonstrated expression in solid cancers and hematological malignancies, such as prostate cancer, melanoma, Hodgkin's lymphoma and Non-Hodgkin's lymphoma, such as T and B cell lymphomas. The different expression profiles of CGEN-15022 and CGEN-15001T not only provide important differentiating characteristics between the two novel targets, but also offer promising opportunities for utilizing these proteins as mAb targets in order to treat a broad set of key cancer indications with significant unmet medical needs.  Full Article

Compugen Ltd And Merck KGaA's Merck Serono Ventures To Jointly Establish New Biomarker Company Neviah Genomics Ltd.
Monday, 25 Jun 2012 07:00am EDT 

Merck Serono, a division of Merck KGaA, and Compugen Ltd. announced the establishment of Neviah Genomics, a start-up company focused on the discovery and development of biomarkers for the prediction of drug-induced toxicity. Neviah Genomics will be operating out of the Merck Serono Israel Bioincubator. Merck Serono Ventures will provide the initial funding for Neviah Genomics. Compugen will utilize certain predictive discovery technologies and receive an equity ownership in the new company and a right to royalties from potential future sales. Further financial details of the agreement were not disclosed. Neviah Genomics represents the first investment within the framework of the recently formed Merck Serono Israel Bioincubator program. As such, Neviah Genomics will operate out of the facilities inaugurated last month at Merck Serono’s Israeli R&D center Inter-Lab, which offers 600 square meters of infrastructure and a wide range of incubation services for the program's new start-ups. This agreement follows a collaboration between Merck Serono and Compugen for the discovery of "biomarker signatures" for drug induced toxicity during 2009.  Full Article

Compugen Ltd. Announces Initial Validation Of Additional B7/CD28 Protein Family Based Product Candidate
Tuesday, 21 Jun 2011 08:06am EDT 

Compugen Ltd. announced today in vitro validation of a second product candidate based on Compugen-discovered novel members of the B7/CD28 co-stimulatory protein family. Proteins belonging to the B7/CD28 family are of high industry interest in view of their key roles in regulating immune response and are viewed as having significant therapeutic potential in multiple areas of important medical need, including autoimmune diseases, transplantation and cancer. The initial prediction and selection activities of this platform have focused on immune related protein families for which additional members are difficult to discover using traditional discovery methods. Analysis of the in silico results from these activities with respect to the B7/CD28 protein family have to date resulted in the identification of nine molecules predicted to be previously unknown members of this intensely and widely studied protein family. The successful in vitro validation and disclosure of CGEN-15021 follows the previously announced CGEN-15001, which was the first product candidate based on a Compugen-discovered novel B7/CD28 family member to undergo extensive validation activities. CGEN-15001 has already demonstrated its therapeutic potential for treatment of multiple sclerosis and rheumatoid arthritis in numerous in vivo studies. Compugen continues to move forward with the development of CGEN-15001 in its Pipeline Program, and is also in discussions with possible partners for its commercialization.  Full Article

  • Previous
  • Next

Compugen Ltd News

» More CGEN.PH News

Earnings vs. Estimates

» More Financials
Search Stocks